- Home
- MIRA vs CASI Comparison
MIRA vs CASI Comparison
Compare MIRA & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- CASI
- Stock Information
- Founded
- MIRA 2020
- CASI 1991
- Country
- MIRA United States
- CASI China
- Employees
- MIRA N/A
- CASI N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- CASI Biotechnology: Pharmaceutical Preparations
- Sector
- MIRA Health Care
- CASI Health Care
- Exchange
- MIRA Nasdaq
- CASI Nasdaq
- Market Cap
- MIRA 19.5M
- CASI 20.5M
- IPO Year
- MIRA 2023
- CASI 1996
- Fundamental
- Price
- MIRA $1.42
- CASI $1.73
- Analyst Decision
- MIRA Strong Buy
- CASI Strong Buy
- Analyst Count
- MIRA 1
- CASI 1
- Target Price
- MIRA $17.00
- CASI $4.00
- AVG Volume (30 Days)
- MIRA 907.1K
- CASI 3.4M
- Earning Date
- MIRA 08-15-2025
- CASI 08-19-2025
- Dividend Yield
- MIRA N/A
- CASI N/A
- EPS Growth
- MIRA N/A
- CASI N/A
- EPS
- MIRA N/A
- CASI N/A
- Revenue
- MIRA N/A
- CASI $31,368,000.00
- Revenue This Year
- MIRA N/A
- CASI N/A
- Revenue Next Year
- MIRA N/A
- CASI N/A
- P/E Ratio
- MIRA N/A
- CASI N/A
- Revenue Growth
- MIRA N/A
- CASI 8.39
- 52 Week Low
- MIRA $0.73
- CASI $1.09
- 52 Week High
- MIRA $2.70
- CASI $7.67
- Technical
- Relative Strength Index (RSI)
- MIRA 44.28
- CASI 56.44
- Support Level
- MIRA $1.35
- CASI $1.46
- Resistance Level
- MIRA $1.77
- CASI $2.57
- Average True Range (ATR)
- MIRA 0.10
- CASI 0.27
- MACD
- MIRA -0.05
- CASI 0.03
- Stochastic Oscillator
- MIRA 15.56
- CASI 36.84
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.